Australia markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
28.19+0.08 (+0.28%)
As of 11:21AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 12.56B
Enterprise value 17.46B
Trailing P/E 11.11
Forward P/E 8.27
PEG ratio (5-yr expected) 1.17
Price/sales (ttm)7.20
Price/book (mrq)1.92
Enterprise value/revenue 7.41
Enterprise value/EBITDA 9.25

Trading information

Stock price history

Beta (5Y monthly) 0.45
52-week change 3-20.03%
S&P500 52-week change 321.08%
52-week high 335.76
52-week low 325.92
50-day moving average 329.63
200-day moving average 328.81

Share statistics

Avg vol (3-month) 32.81M
Avg vol (10-day) 32.73M
Shares outstanding 5446.69M
Implied shares outstanding 6597.44M
Float 8383.82M
% held by insiders 13.83%
% held by institutions 172.23%
Shares short (15 Apr 2024) 414.15M
Short ratio (15 Apr 2024) 45.83
Short % of float (15 Apr 2024) 43.31%
Short % of shares outstanding (15 Apr 2024) 43.17%
Shares short (prior month 15 Mar 2024) 412.65M

Dividends & splits

Forward annual dividend rate 40.84
Forward annual dividend yield 42.99%
Trailing annual dividend rate 30.80
Trailing annual dividend yield 32.85%
5-year average dividend yield 4N/A
Payout ratio 431.62%
Dividend date 314 June 2024
Ex-dividend date 416 May 2024
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 48.20%
Operating margin (ttm)102.82%

Management effectiveness

Return on assets (ttm)5.62%
Return on equity (ttm)17.34%

Income statement

Revenue (ttm)2.35B
Revenue per share (ttm)5.26
Quarterly revenue growth (yoy)5.40%
Gross profit (ttm)N/A
EBITDA 1.5B
Net income avi to common (ttm)1.13B
Diluted EPS (ttm)2.53
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)495.31M
Total cash per share (mrq)1.11
Total debt (mrq)6.14B
Total debt/equity (mrq)60.84%
Current ratio (mrq)7.90
Book value per share (mrq)14.61

Cash flow statement

Operating cash flow (ttm)2.99B
Levered free cash flow (ttm)-1.25B